The Integrated Research Center (CIP), at the Base Hospital of Rio Preto, was one of the international centers qualified to test a new vaccine capable of protecting humans against five different types of meningitis (viral, bacterial, fungal, eosinophilic and aseptic).
The study of the pentavalent immunizer MenACWY-7B, produced by the British laboratory GSK, is already in phase 2 and should be tested in Europe and the Americas in individuals aged between 10 and 25 years, the group most susceptible to meningococcal infection.
According to virologist Maurício Lacerda Nogueira, who coordinates the research at Rio Preto, the drug represents a technological advance because it brings together in a single formula antigens that are currently applied separately, in two or more vaccines included in the national calendar of the Ministry of Health. .
“By reducing the amount of vaccines people have to take, we make room for other vaccinations,” he said.
The aim of the study, according to the expert, is to assess the safety of the new vaccine and the ability of the substance to provoke an immune response, such as the development of antibodies. This is called immunogenicity.
Volunteer registration is now open and can be done by calling (17) 3201-5000 (ext. 1014, 1015 and 5403).
The criteria for participation in the study are: not having received a dose of vaccine against meningitis B; have received the vaccine against meningitis C until the age of two years; have received the ACWY meningitis vaccine more than 4 years ago and have no history of meningococcal disease.
The volunteers will be divided into two groups: control and evaluation. The first will receive two injections of immunizing agent (meningitis B and MenACWY-7B) at the first visit and the second dose of vaccine against meningitis B 121 days later.
The second group will receive three applications, one of placebo and two of the vaccine under investigation, to be defined by the researchers. The first dose will be given at the first visit, the second 121 days later (four months) and the third 181 days later. The survey must be completed within one year.
Meningitis is an inflammation caused by viruses, bacteria or parasites that affects brain structures and can kill two out of ten infected people. Others may suffer permanent sequelae. The evolution of the disease is rapid, so it must be diagnosed as early as possible, for the treatment to be effective.
- Meningitis is an inflammation of the meninges, which are the membranes that surround the brain.
- It is mainly caused by bacteria or viruses and not all of them are contagious or transmissible.
- Meningococcal meningitis is caused by a bacterium, meningococci, and is contagious.
Talking, coughing, sneezing and kissing, moving from one person’s throat to another
Not everyone who gets meningococcus gets sick, because the body defends itself with the antibodies it creates on contact with these same bacteria, thus acquiring resistance to the disease.
Children between the ages of 6 months and 1 year are the most vulnerable to meningococcal disease because they have usually not yet developed antibodies to fight it.
It is a serious disease and we must be attentive to the signs and symptoms because, if diagnosed and treated quickly, it can be cured without leaving sequelae to the patient.
Any case of meningitis must be reported to the health authorities, by the doctor or by the hospital where the patient is being treated.
- high fever
- strong headaches
- vomiting (not always, initially)
- neck stiffness (difficulty moving the head)
- wine stains on the skin
- state of dejection, weakness
In babies we can also observe:
- tense or raised mole
- moan to the touch
- discomfort with high pitched cry
- body rigidity with involuntary movements, or “soft” body, relaxed
- The Integrated Research Center at the Base Hospital will test a vaccine that protects against the five meningococcal serogroups
- Must be between 10 and 25 years old
- Must have no history of previous or current disease caused by meningococcal disease
- May not have had the meningitis B vaccine in their lifetime
- Must have received the ACWY meningitis vaccine more than four years ago
- Must have received meningitis C vaccine at age 2
- Volunteers can apply by calling (17) 3201-5000 ext 1014, 1015 or 5403
Source: Ministry of Health and Base Hospital